I completed my PhD in Physiology and Biophysics (University of Illinois Chicago, USA) in 2013 under the supervision of Dr Beata Wolska and Dr R. John Solaro, where I investigated the functional relevance of modifications within the cardiac myofilament both in the context of Hypertrophic Cardiomyopathy,as well as in acute lipid signalling. For part of this work I was awarded a competitive American Heart Association Pre-doctoral Fellowship. I am currently a post-doctoral researcher within Cardiovascular Medicine, as well as the Co-Director of the Proteomics Training Scheme funded by Oxford's British Heart Foundation Centre for Research Excellence.
In order to maintain cardiac function on a beat-to-beat basis, the heart relies on processes capable of fine-tuning contraction and relaxation. One way this is achieved is through cellular signalling events which result in transient modifications of proteins essential for both intracellular ion fluxing and contractility. While such processes are essential for the heart's normal adaptive response to changing demands, dysregulation of these processes can promote the development and sustainment of disease. My work focuses on the impact of protein modifications, and in particular redox modifications, to ion fluxes and contractility both in the healthy myocardium and in chronic cardiac diseases. I also apply unbiased quantitative assessment of protein modifications, using proteomic approaches, to better understand the key cellular processes altered in cardiac diseases such as atrial fibrillation.
Compromised redox homeostasis, altered nitroso-redox balance, and therapeutic possibilities in atrial fibrillation.
Simon JN. et al, (2016), Cardiovasc Res, 109, 510 - 518
The role of nitric oxide synthase (NOS) and its essential cofactor tetrahydrobiopterin (BH4) in diabetic cardiomyopathy
Duglan D. et al, (2015), EUROPEAN HEART JOURNAL, 36, 775 - 775
NOS/redox-independent protective effects of GTP cyclohydrolase 1 (GCH1) overexpression and tetrahydrobiopterin (BH4) in diabetic cardiomyopathy
Hijazo RC. et al, (2014), EUROPEAN HEART JOURNAL, 35, 1185 - 1186
Increased atrial fibrillation susceptibility in mice with myocardial specific NOX2 overexpression is prevented by short term statin treatment
Recalde A. et al, (2014), EUROPEAN HEART JOURNAL, 35, 1118 - 1118
P683The role of nitric oxide synthase (NOS) and its essential cofactor tetrahydrobiopterin (BH4) in diabetic cardiomyopathy.
Duglan D. et al, (2014), Cardiovasc Res, 103 Suppl 1